Substituted oxazolidinone derivatives
This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and condition that are beneficially treated by administering a selective inhibitor of factor Xa, such as rivaroxaban.
1. A method of inhibiting the activity of coagulation factor Xa in a cell, comprising contacting the cell with a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein each of X 1a , X 1b , X 2a , X 2b , X 3a , and X 3b is deuterium; and Y 1a , and Y 1b are the same and are selected from hydrogen and deuterium.
2. A method of a therapeutic treatment of a disease selected from pulmonary embolism, stroke, thromboembolism, deep venous thrombosis, thrombosis, myocardial infraction, acute coronary syndrome, disorders of coagulation, microangiopathy and thrombocytopenic purpura in a patient in need thereof comprising administering to said patient an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein each of X 1a , X 1b , X 2a , X 2b , X 3a , and X 3b is deuterium; and Y 1a , and Y 1b are the same and are selected from hydrogen and deuterium.
3. The method of claim 2 , wherein the disease is selected from pulmonary embolism, stroke, thromboembolism, deep venous thrombosis, thrombosis, myocardial infarction and acute coronary syndrome.
4. The method of claim 2 , comprising the additional step of co-administering to the patient in need thereof a therapeutic agent useful in the treatment of a disease selected from pulmonary embolism, stroke, thromboembolism, deep venous thrombosis, thrombosis, myocardial infarction, acute coronary syndrome, disorders of coagulation, microangiopathy and thrombocytopenic purpura.
5. The method of claim 3 , comprising the additional step of co-administering to the patient in need thereof a therapeutic agent useful in the treatment of a disease selected from pulmonary embolism, stroke, thromboembolism, deep venous thrombosis, thrombosis, myocardial infarction, acute coronary syndrome, disorders of coagulation, microangiopathy and thrombocytopenic purpura.
6. The method of claim 4 , wherein the disease being treated is acute coronary syndrome; and the therapeutic agent is aspirin.